Record Details

THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY

Medical and Health Science Journal

View Archive Info
 
 
Field Value
 
Title THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY
 
Creator Prasha, Zettira Maulida
Paraton, Hari
 
Subject VULVOVAGINAL ATROPHY
MENOPAUSE
PRASTERONE
PLACEBO
SUPERFICIAL CELL
PARABASAL CELL
VAGINAL PH
DISPAREUNIA
 
Description Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue. Objective : This paper aims to evaluate the effectiveness of administering Prasterone as Vulvovaginal Atrophy therapy in menopausal women. Methods : A systematic data search was performed on a medical database (PUBMED, Google scholar, Cochrane). Inclusion criteria: (1) randomized study of Prasterone as Vulvovaginal Atrophy therapy in postmenopausal women, (2) all-inclusive papers can be accessed completely, and (3) the data obtained can be accurately analysed. Results: Three RCTs with a total of 696 patients were analysed. The average number of Superficial Cells (mean difference [MD] 7.63, and 95% [CI] 7.57 to 7.70 (P <0.00001). The average number of Parabasal Cells (mean difference [MD] -29.84, and 95% [CI] -30.25 to -29.44 (P <0.00001). The average number of vaginal pH (mean difference [MD] -0.69, and 95% [CI] -0.70 to -0.68 (P <0.00001). The average number of Dyspareunia (mean difference [MD] -0.38, and 95% [CI] -0.39 to -0.37 (P <0.00001). All diamonds do not intersect the vertical line, and have p <0.05, it proves that there are significant differences between the two groups. All non-hysterectomized women have an atrophic or inactive endometrium. Side effects that are often complained of is headache and application site discharge. Conclusion This meta-analysis concludes that Prasterone therapy has a significant therapeutic effect for Vulvovaginal Atrophy in menopausal women
 
Publisher UNUSA Press
 
Date 2020-08-28
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
 
Format application/pdf
 
Identifier https://journal2.unusa.ac.id/index.php/MHSJ/article/view/1656
10.33086/mhsj.v4i2.1656
 
Source Medical and Health Science Journal; Vol. 4 No. 2 (2020): AUGUST; 103-108
Jurnal Ilmu Kesehatan dan Kesehatan; Vol 4 No 2 (2020): AUGUST; 103-108
2549-7596
2549-7588
10.33086/mhsj.v4i2
 
Language eng
 
Relation https://journal2.unusa.ac.id/index.php/MHSJ/article/view/1656/1165
 
Rights Copyright (c) 2020 Zettira Maulida Prasha, Hari Paraton
https://creativecommons.org/licenses/by-sa/4.0